020-28823388
——
正高(按姓名排序)
您现在的位置:首页 >> 专家介绍 >> 正高

彭挺生

彭挺生
  • 科  室:病理科
  • 职  称:主任医师
  • 导师资格:硕士生导师
  • 最高学历:博士研究生
出诊时间
周一 周二 周三 周四 周五 周六 周日
上午
下午
晚上
(注:出诊信息仅供参考,有可能随时更新,以门诊公布为准。)

医疗特长(限400字内):
熟练掌握各个系统常规标本、冰冻标本病理诊断技术,专长于淋巴造血系统肿瘤和骨髓病理诊断
研究方向:
骨肉瘤发生发展以及侵袭转移机制的研究

主要教育和工作经历:
1994年毕业于河南医科大学临床医疗系获医学学士; 1998年毕业于中山医科大学基础医学院病理学专业获医学硕士;2004年毕业于中山大学病理学与病理生理学专业获医学博士;1998年至2006年任中山医科大学中山医院病理学教研/附属第一医院病理科助教、讲师;2007年至2014年任中山大学附属第一医院病理科副教授;2009年至2011年在美国德克萨斯大学MD Anderson Cancer Center从事博士后研究工作两年;2015年起任中山大学附属第一医院病理科主任医师。2007年起聘为硕士研究生导师。

社会兼职:
现任广东省医学会病理学分会第十届委员会常务委员;中国抗癌协会肿瘤病理专业委员会青年委员会委员;广东省抗癌协会肿瘤病理专业委员会委员;广东省医疗行业协会病理医学管理分会委员
论著:
共发表论文40余篇,已发表SCI论文20篇。主持国自然、教育部留学回国人员基金、省自然等科研基金项目5项,作为主要参与人参与科研基金7项。主编或参编《病理学》教材/专著8部。
SCI论文:
1.Tian R, Xie X, Han J, Luo C, Yong B, Peng H, Shen J, Peng T.  miR-199a-3p negatively regulates the progression of osteosarcoma through targeting AXL American Journal of Cancer Research. 2014;4(6):738-750. 
2.Han J, Tian R, Yong B, Luo C, Tan P, Shen J, Peng T. Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients. Biochem Biophys Res Commun. 2013 Jun 7;435(3):493-500. 
3.Han J, Yong B, Luo C, Tan P, Peng T, Shen J. High serum alkaline phosphatase cooperating with MMP-9 predicts metastasis and poor prognosis in patients with primary osteosarcoma in Southern China. World J Surg Oncol. 2012 Feb 15;10:37. 
4.Cao Q, Huang Y, Ye Z, Liu N, Li S, Peng T. Primary spleen extranodal NK/T cell lymphoma, nasal type, with bone marrow involvement and CD30 positive expression: a case report and literature review. Diagn Pathol. 2014 Sep 3;9(1):169. 
5.Shi H, Han J, Liu N, Ye Z, Li Z, Li Z, Peng T.  A gangliocytic patially glandular paraganglioma with lymph node metastasis. Diagn Pathol. 2014 Mar 20;9:63.
6.Xu Q, Cao Q, Liu N, Fang Z, Ye Z, Peng T. Renal collecting duct carcinoma with extensive coagulative necrosis mimicking anemic infarct: report of a case and the literature review. Diagn Pathol. 2013 Jul 16;8(1):119.
7.Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R, Young ED, Wang X, Brewer K, López-Terrada DH, Oliveira AM, Lazar AJ, Lev D. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest. 2011 Mar;91(3):392-403. 
8.Zhang Y, Young ED, Bill K, Belousov R, Peng T, Lazar AJ, Pollock RE, Simmons PJ, Lev D, Kolonin MG. Heterogeneity and immunophenotypic plasticity of malignant cells in human liposarcomas. Stem Cell Res. 2013 Sep;11(2):772-81. 
9.Hoffman A, Ghadimi MP, Demicco EG, Creighton CJ, Torres K, Colombo C, Peng T, Lusby K, Ingram D, Hornick JL, Wang WL, Ravi V, Lazar AJ, Lev D, Pollock RE. Localized and metastatic myxoid/round cell liposarcoma: clinical and molecular observations. Cancer. 2013 May 15;119(10):1868-77. 
10.Tan P, Zou C, Yong B, Han J, Zhang L, Su Q, Yin J, Wang J, Huang G, Peng T, Shen J. Expression and prognostic relevance of PRAME in primary osteosarcoma. Biochem Biophys Res Commun. 2012 Mar 23;419(4):801-8.
11.Zhang P, Bill K, Liu J, Young E, Peng T, Bolshakov S, Hoffman A, Song Y, Demicco EG, Terrada DL, Creighton CJ, Anderson ML, Lazar AJ, Calin GG, Pollock RE, Lev D. MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling. Cancer Res. 2012 Apr 1;72(7):1751-62.
12.Demicco EG, Torres KE, Ghadimi MP, Colombo C, Bolshakov S, Hoffman A, Peng T, Bovée JV, Wang WL, Lev D, Lazar AJ. Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma. Mod Pathol. 2012 Feb;25(2):212-21. 
13.Xie X, Ghadimi MP, Young ED, Belousov R, Zhu QS, Liu J, Lopez G, Colombo C, Peng T, Reynoso D, Hornick JL, Lazar AJ, Lev D.  Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin Cancer Res. 2011 Sep 15;17(18):5901-12.
14.Ghadimi MP, Al-Zaid T, Madewell J, Peng T, Colombo C, Hoffman A, Creighton CJ, Zhang Y, Zhang A, Lazar AJ, Pollock RE, Lev D. Diagnosis, management, and outcome of patients with dedifferentiated liposarcoma systemic metastasis. Ann Surg Oncol. 2011 Dec;18(13):3762-70. 
15.Ghadimi MP, Liu P, Peng T, Bolshakov S, Young ED, Torres KE, Colombo C, Hoffman A, Broccoli D, Hornick JL, Lazar AJ, Pisters P, Pollock RE, Lev D. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer. 2011 Dec 1;117(23):5359-69. 
16.Ye Z, Shi H, Peng T, Han A. Clinical and pathological features of high grade primary cardiac osteosarcoma. Interact Cardiovasc Thorac Surg. 2011 Jan;12(1):94-5. 
17.Wang A, Liu X, Sheng S, Ye H, Peng T, Shi F, Crowe DL, Zhou X. Dysregulation of heat shock protein 27 expression in oral tongue squamous cell carcinoma. BMC Cancer. 2009 Jun 4;9:167. 
18.Ye H, Wang A, Lee BS, Yu T, Sheng S, Peng T, Hu S, Crowe DL, Zhou X. Proteomic based identification of manganese superoxide dismutase 2 (SOD2) as a metastasis marker for oral squamous cell carcinoma. Cancer Genomics Proteomics. 2008 Mar-Apr;5(2):85-94.
19.Wang L, Li HG, Wen JM, Peng TS, Zeng H, Wang LY.  Expression of CD44v3, erythropoietin and VEGF-C in gastric adenocarcinomas: correlations with clinicopathological features. Tumori. 2014 May-Jun;100(3):321-327
20.Wang L, Li HG, Xia ZS, Lü J, Peng TS. IMP3 is a novel biomarker to predict metastasis and prognosis of gastric adenocarcinoma: a retrospective study. Chin Med J (Engl). 2010 Dec;123(24):3554-8.